Vita Life Sciences Ltd
ASX:VLS
Relative Value
The Relative Value of one
VLS
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 2.6 AUD,
Vita Life Sciences Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
VLS Competitors Multiples
Vita Life Sciences Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Vita Life Sciences Ltd
ASX:VLS
|
145.4m AUD | 1.7 | 15.6 | 9.2 | 9.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD | 15.2 | 48.1 | 32.4 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.5B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
283.1B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.6B CHF | 5.3 | 21.3 | 13.2 | 16.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.3B GBP | 5.2 | 32 | 15.3 | 22.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.1B USD | 4.5 | 16 | 10 | 11.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.6 | 10 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD | 2.6 | 17.5 | 6.8 | 8.8 |